Positive Phase III Data for Genentech's Gazyva Show Significant Reduction in Disease Activity for Systemic Lupus Erythematosus

Core Insights - Genentech, a member of the Roche Group, announced significant results from the Phase III ALLEGORY study of Gazyva (obinutuzumab) for adults with systemic lupus erythematosus (SLE) [1] Study Results - The study met its primary endpoint, demonstrating a higher percentage of patients achieving a minimum four-point improvement in SLE Responder Index 4 (SRI-4) at one year (52 weeks) with Gazyva [1]